

Initial Prior Authorization with Quantity Limit Dibenzylamine

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Dibenzylamine	phenoxybenzamine

Indications

FDA-Approved Indications

Dibenzylamine is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly.

Compendial Uses

Paraganglioma^{5,6}

Coverage Criteria

Pheochromocytoma, Paraganglioma

Authorization may be granted when the requested drug is being prescribed for the treatment of

Reference number(s)
3673-C

pheochromocytoma or paraganglioma to control episodes of hypertension and sweating when ONE of the following criteria are met:

- The patient has experienced an inadequate treatment response to an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)
- The patient has experienced an intolerance to an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)
- The patient has a contraindication that would prohibit a trial of an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)

Quantity Limits Apply

360 capsules per 25 days or 1,080 capsules per 75 days

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Duration of Approval (DOA)

- 3673-C: DOA: 12 months

References

1. Dibenzyline [package insert]. Dublin 9, Ireland: Amdipharm Limited; April 2020.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed May 10, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 05/10/2024).
4. Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. The New England Journal of Medicine 2019; 381:552-65.
5. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2014;99(6):1915-1942.
6. Neuroendocrine and Adrenal Tumors. NCCN Guidelines version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed May 23, 2024.